216 related articles for article (PubMed ID: 22211100)
21. Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer.
Lee SH; Ryu JK; Lee KY; Woo SM; Park JK; Yoo JW; Kim YT; Yoon YB
Cancer Lett; 2008 Jan; 259(1):39-49. PubMed ID: 17967505
[TBL] [Abstract][Full Text] [Related]
22. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.
El-Rayes BF; Ali S; Ali IF; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2006 Nov; 66(21):10553-9. PubMed ID: 17079479
[TBL] [Abstract][Full Text] [Related]
23. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.
Liu J; Ma J; Wu Z; Li W; Zhang D; Han L; Wang F; Reindl KM; Wu E; Ma Q
BMC Cancer; 2014 Sep; 14():686. PubMed ID: 25240403
[TBL] [Abstract][Full Text] [Related]
24. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
Ng SS; Tsao MS; Nicklee T; Hedley DW
Mol Cancer Ther; 2002 Aug; 1(10):777-83. PubMed ID: 12492110
[TBL] [Abstract][Full Text] [Related]
25. Effects of evodiamine on PI3K/Akt and MAPK/ERK signaling pathways in pancreatic cancer cells.
Hong Z; Wang Z; Zhou B; Wang J; Tong H; Liao Y; Zheng P; Jamshed MB; Zhang Q; Chen H
Int J Oncol; 2020 Mar; 56(3):783-793. PubMed ID: 31922213
[TBL] [Abstract][Full Text] [Related]
26. Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
Ali S; Banerjee S; Schaffert JM; El-Rayes BF; Philip PA; Sarkar FH
J Cell Biochem; 2010 May; 110(1):171-81. PubMed ID: 20213764
[TBL] [Abstract][Full Text] [Related]
27. Piperlongumine Suppresses Growth and Sensitizes Pancreatic Tumors to Gemcitabine in a Xenograft Mouse Model by Modulating the NF-kappa B Pathway.
Wang Y; Wu X; Zhou Y; Jiang H; Pan S; Sun B
Cancer Prev Res (Phila); 2016 Mar; 9(3):234-44. PubMed ID: 26667450
[TBL] [Abstract][Full Text] [Related]
28. miRNA-93-5p Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Targeting the PTEN-Mediated PI3K/Akt Signaling Pathway.
Wu Y; Xu W; Yang Y; Zhang Z
Ann Clin Lab Sci; 2021 May; 51(3):310-320. PubMed ID: 34162560
[TBL] [Abstract][Full Text] [Related]
29. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
Zhuang Z; Li H; Lee H; Aguilar M; Gocho T; Ju H; Iida T; Ling J; Fu J; Wu M; Sun Y; Lu Y; Chiao PJ
Cancer Lett; 2017 Dec; 411():44-56. PubMed ID: 28951128
[TBL] [Abstract][Full Text] [Related]
30. [Experimental study of the function and mechanism combining dihydroartemisinin and gemcitabine in treating pancreatic cancer].
Wang SJ; Sun B; Pan SH; Chen H; Kong R; Li J; Xue DB; Bai XW; Jiang HC
Zhonghua Wai Ke Za Zhi; 2010 Apr; 48(7):530-4. PubMed ID: 20646665
[TBL] [Abstract][Full Text] [Related]
31. Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway.
Wang Y; Zhou Y; Jia G; Han B; Liu J; Teng Y; Lv J; Song Z; Li Y; Ji L; Pan S; Jiang H; Sun B
Biochem Pharmacol; 2014 Apr; 88(3):322-33. PubMed ID: 24522113
[TBL] [Abstract][Full Text] [Related]
32. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.
Arlt A; Gehrz A; Müerköster S; Vorndamm J; Kruse ML; Fölsch UR; Schäfer H
Oncogene; 2003 May; 22(21):3243-51. PubMed ID: 12761494
[TBL] [Abstract][Full Text] [Related]
33. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
[TBL] [Abstract][Full Text] [Related]
34. Vitamin E δ-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-κB activation in pancreatic cancer.
Husain K; Francois RA; Yamauchi T; Perez M; Sebti SM; Malafa MP
Mol Cancer Ther; 2011 Dec; 10(12):2363-72. PubMed ID: 21971120
[TBL] [Abstract][Full Text] [Related]
35. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.
El-Rayes BF; Philip PA; Sarkar FH; Shields AF; Ferris AM; Hess K; Kaseb AO; Javle MM; Varadhachary GR; Wolff RA; Abbruzzese JL
Invest New Drugs; 2011 Aug; 29(4):694-9. PubMed ID: 20107864
[TBL] [Abstract][Full Text] [Related]
36. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
[TBL] [Abstract][Full Text] [Related]
37. Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-κB-mediated survival signaling pathways in human gallbladder cancer cells.
Yu Y; Wang J; Xia N; Li B; Jiang X
Oncol Rep; 2015 Apr; 33(4):1683-90. PubMed ID: 25633045
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-κB signaling by 6-shogaol.
Zhou L; Qi L; Jiang L; Zhou P; Ma J; Xu X; Li P
AAPS J; 2014 Mar; 16(2):246-57. PubMed ID: 24424498
[TBL] [Abstract][Full Text] [Related]
39. Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study.
Brandi G; Tavolari S; Guarnieri T; Di Marco M; Paterini P; Macchini M; Di Girolamo S; Papi A; De Rosa F; Biasco G
Pancreas; 2014 Jan; 43(1):53-63. PubMed ID: 24201777
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter‑1 and lactate dehydrogenase A.
Xu D; Zhou Y; Xie X; He L; Ding J; Pang S; Shen B; Zhou C
Int J Oncol; 2020 Nov; 57(5):1223-1233. PubMed ID: 32901837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
